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Summary
Introduction: Cleavage of aggrecan between residues Glu373–Ala374, which is believed to be a key event in aggrecan destruction in arthritic
diseases, has been attributed to an enzymatic activity, aggrecanase. Two cartilage aggrecanases have been identified, aggrecanase-1
(ADAM-TS4) and aggrecanase-2 (ADAM-TS5) and both enzymes have been shown very efficiently to cleave soluble aggrecan at the
Glu373–Ala374 site.
Objective: To determine whether ADAM-TS4 and/or ADAM-TS5 are the aggrecanases responsible for aggrecan catabolism following
interleukin-1 (IL-1) and tumor necrosis factor (TNF) treatment of bovine articular cartilage.
Results: (1) IL-1- and TNF-stimulated release of aggrecan was associated with cleavage of aggrecan within the C-terminus at the ADAM-TS4
and ADAM-TS5-sensitive sites, Glu1480–Gly1481, Glu1667–Gly1668, and Glu1871–Leu1872. (2) The order of cleavage following IL-1 stimulation
of cartilage explants was the same as when soluble aggrecan is digested with recombinant human ADAM-TS4 and ADAM-TS5. (3) Both
constitutive and stimulated cleavage of aggrecan at the ADAM-TS4 and ADAM-TS5-sensitive sites in cartilage was blocked by a general
metalloproteinase inhibitor but not by a MMP-specific inhibitor, and this inhibition correlated with inhibition of aggrecan release from cartilage.
(4) PCR and Western blot analysis indicated that both ADAM-TS proteases are expressed in cartilage explants; ADAM-TS5 is constitutively
expressed whereas ADAM-TS4 is induced following IL-1 and TNF treatment. (5) Immunodepletion of both ADAM-TS4 and ADAM-TS5 from
bovine articular cartilage cultures following IL-1 stimulation resulted in a 90% reduction of aggrecanase activity in the culture medium.
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Cartilage degradation is the hallmark of rheumatoid arthritis
(RA) and osteoarthritis (OA). The major components of the
cartilage extracellular matrix are type II collagen and aggre-
can. Aggrecan monomers are approximately 2.5 million
Daltons and consist of a 250-kD protein core with chondroi-
tin sulfate and keratan sulfate glycosaminoglycan (GAG)
side chains attached to it. The amino terminal region of the
aggrecan core protein contains two globular domains, G1
and G2, which are separated by an interglobular domain
(IGD) that spans about 150 amino residues. The G2 region
is followed by a long GAG attachment region and by the
carboxyl terminal globular domain G31,2. Aggrecan mono-
mers interact with hyaluronan through their G1 domain and
thus form large aggregates containing 10–100 aggrecan
monomers on a hyaluronan backbone. Because aggrecan
provides cartilage with its properties of compressibility and
elasticity by swelling and hydrating the collagen framework,539the loss of aggrecan from the matrix is a key event in
cartilage destruction. Indeed, one of the earliest changes
observed in osteoarthritis is the loss of aggrecan from the
cartilage matrix3.
Aggrecan depletion in arthritic cartilage has been
ascribed to increased proteolytic cleavage of the core
protein. Two major cleavage sites have been identified in
the IGD, one at Asn341–Phe342 and one at the Glu373–
Ala374 bond. Matrix metalloproteinases (MMP) act primarily
on the former bond and all MMPs found to be present in
cartilage including MMP-1, MMP-2, MMP-3, MMP-7,
MMP-8, MMP-9, MMP-13, and MT1-MMP, are capable of
cleaving aggrecan at this site in vitro4–7. Cleavage at
the second site, Glu373-Ala374, has been attributed to an
enzymatic activity referred to as aggrecanase8–11.
Since the discovery of aggrecanase activity, we have
identified and cloned two cartilage aggrecanases,
aggrecanase-112 and aggrecanase-213. Both enzymes are
members of the a disintegrin and metalloprotease (ADAM)
family of zinc metalloproteases that consist of an amino-
terminal propeptide domain, a metalloproteinase domain,
and a disintegrin-like domain, resembling the structural
elements of the reprolysin family of metalloproteases14.
Unlike typical ADAM proteins that are membrane-anchored
and have a transmembrane and a cytoplasmic domain in
the carboxyl terminal region, the C-terminal half of
aggrecanase-1 and aggrecanase-2 contains a varying
number of thrombospondin (TS) type 1 motifs, the
sequence of which is the conserved motif in thrombo-
spondin 1 and 2. ADAM proteins containing these TS motifs
are referred to as ADAM-TS proteins, and aggrecanase-1
540 M. D. Tortorella et al.: ADAM-TS4/TS5 in cartilage aggrecan breakdownFig. 1. Schematic representation of MMP- and ADAM-TS4- and ADAM-TS5-generated fragments of bovine aggrecan. (a) ADAM-TS4 and
ADAM-TS5 cleavage sites within bovine aggrecan. (b) MMP- and ADAM-TS-generated fragments.
a
band aggrecanase-2 have been designated ADAM-TS4 and
ADAM-TS5, respectively.
Both enzymes have been shown to cleave within the IGD
at the aggrecanase site between residues Glu373 and
Ala374, but not at the MMP site between residues Asn341
and Phe342. In addition, we have recently demonstrated
that human recombinant ADAM-TS4 and ADAM-TS5 both
cleave aggrecan preferentially at four sites located in the
chondroitin sulfate-rich region between G2 and G3 at the
Glu1480–Gly1481, Glu1667–Gly1668, Glu1771–Ala1772 and
Glu1871–Leu1872 bonds (15 and Tortorella et al., in prep-
aration) (Fig. 1). Two of these sites correspond withfragments previously reported to be released during
IL-1alpha-treatment of bovine articular cartilage suggesting
cleavage at the Glu1771–Ala1772 and Glu1871–Leu1872
bonds16,17. Cleavage of cartilage aggrecan within the IGD
between amino acids Glu373 and Ala374 results in the
formation of a small N-terminal fragment with a new
C-terminus NITEGE373 and a large C-terminal fragment
with the new N-terminus 374ARGSV. Researchers have
designed antibodies to these neoepitopes and are currently
using them to monitor aggrecanase-mediated cleavage.
However, using these antibodies to confirm that ADAM-
TS4/TS5 are responsible for endogenous aggrecanase
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Glu373–Ala374 bond by MMP-818 and MT1-MMP19. There-
fore, in the present study, we investigated whether MMP-8
and MT1-MMP cleave aggrecan at the ADAM-TS4/TS5
preferential sites of cleavage within the C-terminus of
aggrecan. Furthermore, we employed neoepitope anti-
bodies to the products of ADAM-TS4/5 cleavage in the
C-terminus of aggrecan, selective inhibitors, evaluation of
ADAM-TS4/TS5 message and protein, and immuno-
depletion to elucidate whether these aggrecanases are
critical for the breakdown of aggrecan during IL-1- and
TNF-induced degradation of articular cartilage explants.Method
MATERIALS
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf
serum (FCS) and penicillin/streptomycin were purchased
from BioWhittakers (Verviers, Belgium). IL-1 and IL-1
receptor antagonist (IL-1ra) were a gift from Dr Jerry
Saklatvala (Kennedy Institute of Rheumatology, London,
U.K.)20. TNF was a gift from Professor W. Stec (Centre
of Molecular and Macromolecular Biology, Lodz, Poland)
and neutralizing anti-TNF antibodies (A2) were a gift
from Centocor Inc (Malvern, PA, U.S.A.). Keratanase,
keratanase II and chondroitinase ABC were from
Seikagaku (Kogyo, Japan). Full length MMP-8 were cloned
and expressed in E. coli at DuPont Pharmaceuticals. MT1-
MMP was a gift from Dr Duanqing Pei (University of
Minnesota, Minneapolis, MN). Antibody BC-321 that
recognizes the new N-terminus ARGS on aggrecan frag-
ments produced by cleavage at the Glu373–Ala374 bond,
was licensed from Dr Bruce Caterson (University of Wales,
Cardiff, U.K.). Antibody AF-2822 that recognizes the new
N-terminus, FFGVG, on aggrecan fragments produced by
cleavage at the Asn341–Phe342 bond, was a gift from
Dr Amanda Fosang (University of Melbourne, Parkville,
Australia). The hydroxamic acids XS309 ([3S-[3R*,
2-[2R*,2-(R*,S*)]-hexahydro-2-(2-[2-(hydro xyamino)-1-
methyl-2-oxyethyl]-4-methyl-1-oxypentyl]-N-methyl-3-p
yridazinecarboxamide) and SE206 (2S,2R,6S-3-aza-4-
oxo-10-oxa-5-hexyl-2-(methylcarboxamido)-10-pa racyclo-
phane-6-N hydroxycarboxamide) were synthesized at
DuPont Pharmaceuticals23,24. The IC50 values of these
compounds against MMP-1, -2, -3, -8, -9 and 14 were
calculated using the fluorogenic peptide substrate, Mca-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, at a concentration of
1 M, and those compounds against ADAM-TS4 and
ADAM-TS5 were determined using 500 mM purified bovine
nasal aggrecan as previously described25. XS309 is a
nanomolar inhibitor of a large number of MMPs, but is
inactive at >10 M in blocking ADAM-TS4/TS5. In con-
trast, SE206 is a nanomolar inhibitor of both MMPs and
ADAM-TS4/TS5. The IC50 value of SE206 against
ADAM-TS4 is 76 nM12, and against ADAM-TS513 is 40 nM.
ADAM-TS5, ADAM-TS4 and ADAM-TS1 were cloned and
expressed in Drosophila S2 cells as described12,13.NEOEPITOPE ANTIBODIES
Polyclonal neoepitope antibodies were prepared to the
peptide sequences DFVDIPES, PRNITEGE, ATTAGELE
and PTTFKEEE that are present on the C-terminus of
aggrecan fragments generated by cleavage at the Ser341–
Phe342 bond, at the Glu373–Ala374 bond, at the Glu1480–Gly1481 bond, and at the Glu1667–Gly1668 bond,
respectively, as described15. A polyclonal neoepitope anti-
body was also prepared to the peptide sequence
1872LGQRPPVT that is present on the N-terminus of aggre-
can fragments generated by cleavage at the Glu1871–
Leu1872 bond [Fig. 1(a)]. Specificity of the antibodies was
determined and intact undigested aggrecan was not
detected with any of the antibodies15. In bovine aggrecan,
cleavage at the Glu1480-Gly1481 bond generates the
C-terminal neoepitope GELE rather than the SELE
neoepitope of the human aggrecan fragment with a single
amino acid substitution of G for S in the P4 position. In
addition, the IPEN C-terminal neoepitope generated by
cleavage at the Asn341–Phe342 bond in the IGD of human
aggrecan is IPES in bovine aggrecan with a single amino
acid substitution of N for S at the P1 position. The antibody
raised against the GELE neoepitope does not recognize
the C-terminus SELE and the antibody raised against the
IPES neoepitope does not recognize the C-terminus IPEN
on the human aggrecan fragment illustrating the high
degree of specificity of these antibodies.ADAM-TS ANTIBODIES
Polyclonal antibodies for ADAM-TS5, ADAM-TS4 and
ADAM-TS1 were prepared to the peptide sequences
ILTSIDASKP (residues 502–511), VMAHVDPEEP (resi-
dues 502–511) and DAKQCASLNG (residues 481–490),
respectively12,13. The antibodies were all purified over a
protein G-Sepharose column and the protein concentration
was determined using BCA reagent (Pierce, Rockford, IL).
The immunizing peptide for each antibody blocked bind-
ing to the antigen and the antibody to ADAM-TS1 did
not cross-react with ADAM-TS4/TS5, the antibody to
ADAM-TS4 did not cross-react with ADAM-TS5, and
finally, the antibody to ADAM-TS5 did not cross-react with
ADAM-TS4 (Fig. 2).RT-PCR FOR ADAM-TS4 AND ADAM-TS5
RNA was isolated from cartilage using RNeasy
Mini-columns (QIAGEN Ltd, U.K.) and then converted into
DNA using Superscript II (Gibco). RT-PCR reactions were
performed using Ready-To-Go PCR beads (Amersham
Pharmacia, Piscataway, NJ). For ADAM-TS4 the primers
used were 5′-ACCACTTTGACACAGCCATTC-3′ (forward,
catalytic domain) and 5′-ACCCCCACAGGTCCGAGA
GCA-3′ (reverse, thrombospondin motif). For ADAM-TS5
the primers used were 5′-TGTGCTGTGATTGAAGAC
GAT-3′ (forward, catalytic domain) and 5′-GACTGCAGGA
GCGGTAGATGG-3′ (reverse, thrombospondin motif). For
bovine glyceraldehyde phospate dehydrogenase (GAPDH)
the primers used were 5′-TGGTATCGTGGAAGGACT
CAT-3′ (forward) and 5′-GTGGGTGTCGCTGTTGAA
GTC-3′ (reverse). The primers for ADAM-TS4 and
ADAM-TS5 are derived from the human sequence, and
were found to cross react with bovine cDNA.BOVINE ARTICULAR CARTILAGE CULTURE
Articular cartilage was dissected from the knees of
6-year-old cows. Cartilage was allowed to equilibrate for
3 days in DMEM supplemented with 10% FCS, penicillin
(100 U/ml) and streptomycin (100 g/ml). Subsequently,
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mately 10–20 mg each, and incubated in 96-well plates for
72 h with either control medium (serum-free DMEM), IL-1
(100 ng/ml), TNF (100 ng/ml), IL-1 (100 ng/ml) plus IL-1ra
(10 g/ml), or TNF (100 ng/ml) plus anti-TNF antibodies
(10 g/ml). For the inhibition studies with SE206 and
XS309, cartilage was dissected from the knees of calves
and incubated in 96-well plates for 72 h with either control
medium, IL-1 (100 ng/ml), IL-1 (100 ng/ml) plus XS309
(10 M), or IL-1 (100 ng/ml) plus SE206 (10 M).EXTRACTION OF AGGRECAN AND ITS CATABOLITES FROM
CARTILAGE
At the end of the 72 h culture period, proteoglycans were
extracted from the cartilage explants for 48 h at 4°C with
4 M guanidinium hydrochloride, 50 mM sodium acetate
buffer, pH 6.8, containing disodium EDTA (0.01 M),
6-aminohexanoic acid (0.1 M), benzamidine hydrochloride
(0.05 M), phenylmethanesulfonylfluoride (2 mM). Extracts
were then dialysed in water.GLYCOSAMINOGLYCAN ASSAY
Glycosaminoglycan (GAG) levels in the culture media
and cartilage extracts were determined by the dimethyl-
methylene blue (DMMB) assay, as described by Farndale
et al.26. Shark chondroitin sulfate was used as a standard,
and results were expressed as g of GAG per mg of wet
weight cartilage.DEGLYCOSYLATION OF AGGRECAN AND AGGRECAN CATABOLITES
Proteoglycans and their breakdown products were
digested with keratanase (0.01 units per g GAG),
keratanase II (0.001 units per g GAG), and chondroitinase
ABC (0.01 units per g GAG) in buffer containing 50 mM
sodium acetate, 0.1 M Tris-HCl, pH 6.5, at 37°C for 3 h.
After digestion the aggrecan was precipitated with 5 vol-umes of acetone and reconstituted in 30 l of Tris glycine/
SDS sample buffer containing 2.5% -mercaptoethanol
and heated for 3 min at 100°C.Fig. 2. Monospecificity of antisera to ADAM-TS4 and ADAM-TS5. Twenty ng of ADAM-TS4 (panel A) or ADAM-TS5 (panel B) were separated
by SDS-PAGE, transferred to PVDF membranes, and incubated with antibodies at a concentration of 10 g/ml to (A) ADAM-TS1,
(B) ADAM-TS4, (C) ADAM-TS5 (D) ADAM-TS4 with 100 M of peptide VMAHVDPEEP, (E) ADAM-TS4 with 100 M of peptide ILTSIDASKP,
(F) ADAM-TS5 with 100 M of peptide VMAHVDPEEP, and (G) ADAM-TS5 with 100 M of peptide ILTSIDASKP.WESTERN BLOT ANALYSIS
Culture media and cartilage extracts were analysed by
SDS-PAGE on 4–12% polyacrylamide gels under reducing
conditions. When analysing culture media for aggrecan
catabolites, equal volumes (20 l, i.e. 10% of the culture
medium) were loaded. When analysing cartilage matrix
extracts for aggrecan catabolites, gels were loaded on an
equal GAG basis (20 g). The separated proteins were
transferred to PVDF membranes and immunolocalized with
a 1:1000 dilution of one of the neoepitope antibodies or
with the antibodies against ADAM-TS4 or ADAM-TS5.
Subsequently, the membranes were incubated with a
1:5000 dilution of goat antimouse or goat antirabbit IgG
alkaline phosphatase conjugate as the secondary antibody.
Products were visualized by developing the blots in
5-bromo-4-chloro-3-indolyl-1-phosphate nitro blue tetrazo-
lium color developing reagent. Overnight transfer resulted
in complete transfer of both low and high molecular
fragments. For monitoring the order in which 374ARGS-,
GELE1480- and KEEE1667-reactive fragments are gener-
ated in cartilage following IL-1 stimulation, conditions of
the Western blot analysis were adjusted to provide equal
intensity of staining for equivalent amounts of antigen. The
antibodies exhibited different affinities for their respective
peptide antigens. Therefore, in order to attain equal
reactivity for the Western analysis, the dilution of each
antibody that yielded an optical density (OD) of 0.5 was
used. This antibody dilution was determined by ELISA, as
follows. The immunizing peptide for each antibody was
linked to biotin at the N-terminus or C-terminus and was
then immobilized at a concentration of 10 nM on a 96-well
streptavidin-coated plate. Varying concentrations of each
antibody, ranging from 1:10 to 1:100,000 dilutions, were
added, followed by a rabbit IgG second antibody conju-
gated to alkaline phosphatase. Binding was assessed
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para-nitrophenyl phosphate substrate (pNPP) and monitor-
ing OD at 405 nm. The dilution that yielded an OD of 0.5 for
the KEEE antibody was a 1:20,000 dilution, for the GELE
antibody a 1:10,000 and for the BC-3 antibody a 1:1000
dilution. Biotin was incorporated to the N terminus of the
ATTAGELE and PTTFKEEE peptides using the solid phase
step-wise synthesis (SPSS) process on an automated
synthesizer. The completed peptide chain (synthesized by
standard Fmoc chemistry) was first extended at the N
terminus with one residue of a 7-atom spacer molecule
(6-aminohexanoic acid). This was followed by addition of
the biotin to the spacer. The reaction is a condensation
between the carboxyl of the biotin and the N-amino of the
6-aminohexanoic acid using standard activation chemistry.
The biotin was used in the same mass excess as the amino
acids for the synthesis of the peptide. As biotin has low
solubility in peptide synthesis solvents it was pre-dissolved
in DMSO before delivery to the reaction vessel. The com-
plete biotinylated peptide was cleaved from the solid phase
and fully deprotected using standard methods. The product
was precipitated with methyl tertiary butyl ether (MTBE),
washed twice with MTBE, dried, dissolved in water and
analysed by RPHPLC (C8). Purification was performed
by RPHPLC (C8) using water/acetonitrile gradient with
trifluoracetic acid as counter ion. Collected fractions were
analysed by RPHPLC (C8) and an homogeneous pool was
formed. This was freeze-dried and sealed under vacuum.
The mass of the product was confirmed by MALDIMS.
C-terminal biotinylation of the ARGSVIL peptide was done
at QCB (Hopkinton, MA).IMMUNODEPLETION OF ADAM-TS1, ADAM-TS4, AND ADAM-TS5
1.5 g of rabbit polyclonal antibody for ADAMTS-1,
ADAMTS-4 or ADAMTS-5 was coupled to 25 l of protein
G-Sepharose (Amersham-Pharmacia). 200 l of culture
media from the 72 h treated bovine articular cartilage
explants, containing endogenous aggrecanase activity
were incubated with the antibody-coupled Sepharose for
2 h at 4°C with constant rotation in a tube rotator. The
samples were then centrifuged and the immuno-depleted
media were removed. In order to remove pre-existing
aggrecan fragments from the media the material was next
passed over a Q5-anion exchange membrane adsorber
(Sartorius, Goettingen, Germany). Both ADAM-TS4 and
ADAM-TS5 have been shown not to bind to a Q-column,
with a recovery of 92% and 90%, respectively. The
ADAM-TS-depleted medium were then assessed for
aggrecanase activity by incubating with purified aggrecan
(500 nM) for 4 h at 37°C in 50 mM Tris, 150 mM NaCl,
10 mM CaCl, pH 7.5 buffer and the digests were monitoredfor products formed by cleavage at the Glu373–Ala374 bond
using a BC-3 ELISA. The efficiency of immunoprecipitation
has been determined for each antibody. Both the ADAM-
TS4 and ADAM-TS5 antisera successfully removed 100 ng
of enzyme that was added to 1 ml of DMEM medium. In
order to determine the efficiency of the ADAM-TS1 immuno-
precipitation, we looked at removal of enzyme by Western
Blot analysis, and we achieved removal of >95% of
ADAM-TS1 from DMEM medium.ResultsCLEAVAGE OF AGGRECAN BY METALLOPROTEINASES
First, we wanted to determine whether MMP-8 or
MT1-MMP could cleave cartilage aggrecan at the
ADAM-TS4/TS5-preferred sites, between Glu373 and
Ala374, Glu1480 and Gly1481, Glu1667 and Gly1668, Glu1771
and Ala1772, and Glu1871 and Leu1872. In these studies
MMP-8 and MT1-MMP were incubated at a concentration
of 100 nM with 500 nM of bovine nasal aggrecan for 2 and
24 h at 37°C. As expected, they cleaved aggrecan between
residues Ser341 and Phe342 to generate DIPES341 and
342FFGVG neoepitopes, which were detected at both 2 and
24 h. However, neither of the MMPs under these exper-
imental conditions were able to produce any of the
aggrecanase-derived neoepitopes with the exception of
MMP-8, which cleaved aggrecan in the interglobular
domain between residues Glu373 and Ala374 to generate a
NITEGE373 and 374ARGS aggrecan fragment at 24 h
(Table I). However, MMP-8 did not cleave the C-terminal
bonds that are readily hydrolysed by ADAM-TS4 and
ADAM-TS5. Therefore, neoepitope antibodies to aggrecan
fragments generated by cleavage at the ADAM-TS4/TS5
preferred sites provide a more specific tool for studying
the involvement of aggrecanases in cartilage aggrecan
breakdown.Table I
Cleavage of aggrecan by metalloproteinases*†
Protease MMP-epitopes Aggrecanase-derived epitopes
IPES FFGV TEGE ARGS KEEE GLGS GELE AGEG LGQR
ADAM-TS4 — — + + + + + + +
ADAM-TS5 — — + + + + + + +
MMP-8 + + + + — — — — —
MT1-MMP + + — — — — — — —
*Metalloproteinases (100 nM) and ADAM-TS proteins (10 nM) were incubated with 500 nM of aggrecan for 24 h at 37°C. Following the
incubation, the products were analysed for MMP-generated neoepitopes and aggrecanase-generated neoepitopes by Western blot analysis.
†+Indicates presence and — indicates absence of neoepitope-reactive bands.IL-1- OR TNF-INDUCED GAG RELEASE FROM CARTILAGE EXPLANTS
CORRELATES WITH AGGRECANASE-GENERATED BUT NOT
MMP-GENERATED NEOEPITOPES FROM AGGRECAN CLEAVAGE
WITHIN THE INTERGLOBULAR DOMAIN
Cartilage explants were cultured in the absence or
presence of IL-1, TNF, IL- plus IL-1ra, or TNF plus
neutralizing anti-TNF antibody. After 72 h, media were
collected for the measurement of GAG content. As
expected, both IL-1 and TNF induced an increased
release of GAG into the culture medium, as a result of
degradation of aggrecan (Table II). IL-1-induced GAG
release was inhibited by the addition of excess IL-1ra, and
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thus demonstrating that the observed cytokine effects were
specific.
These same culture media were analysed for cleavage
of aggrecan within the IGD at the aggrecanase site
between residues Glu373 and Ala374 and at the MMP site,
between residues Asn341 and Phe342. Using the mono-
clonal antibodies BC-3 and AF-28, the culture media were
analysed for aggrecan products with the MMP-generated
342FFGV N-terminus and aggrecanase-generated
374ARGS N-terminus. No FFGV-reactive fragments
(A-fragment) were detected [Fig. 3(a)], but an array of
aggrecan fragments with the N-terminus ARGS(B-fragment) was present in the culture media of both
IL-1- and TNF-stimulated cartilage [Fig. 3(b)].
The cartilage extracts were then analysed for the G1
fragments with the MMP-generated IPES341 neoepitope
and aggrecanase-generated TEGE373 neoepitope. Basal
levels of the IPES341 neoepitope were detected in unstimu-
lated cartilage, seen as a triplet near ∼64 kDa (C-fragment)
and no significant induction of this epitope occurred with a
72-hour cytokine stimulation (Fig. 3(c)]. To eliminate the
possibility that FFGV-containing fragments accumulate in
the cartilage extracellular matrix, we analysed the extracts
for these fragments (A-fragment) and could not detect any
(data not shown). The TEGE373 neoepitope, seen as a
doublet between 90 kDa and 64 kDa (D-fragment), was not
present in unstimulated cartilage, but was strongly induced
by IL-1 and to a lesser degree by TNF [Fig. 3(d)]. The
actions of both IL-1 and TNF in inducing cleavage at the
aggrecanase-sensitive Glu373–Ala374 bond within the IGD
were abolished by the addition of IL-1ra and anti-TNF-
antibody, respectively. These results confirm that the GAG
release observed after a 72-h stimulation with IL-1 or TNF
is mediated by the cleavage of aggrecan within the IGD by
aggrecanase and not MMP activity.Table II
Cytokine-induced degradation of aggrecan in bovine articular
cartilage explants*
Treatment GAG Levels
(g/mg)
Control 1.8
IL-1 [100 ng/ml] 19.5
TNF [100 ng/ml] 18.8
IL-1+IL-1ra [10 g/ml] 4.7
TNF+anti-TNF [10 g/ml] 2.9
*Bovine cartilage explants were incubated for 72 h with
cytokines at the specified concentrations. At the end of the culture
period, media were analysed for GAG content by DMMB assay.Fig. 3. Cytokine-induced degradation of aggrecan in bovine articular cartilage explants. Bovine cartilage explants were incubated for 72 h
with (a) control media or media containing either (b) IL-1 (100 ng/ml), (c) TNF (100 ng/ml), (d) IL-1 plus IL-1ra (10 g/ml), or (e) TNF plus
neutralizing antibodies (10 g/ml). At the end of the culture period, media were analysed for aggrecan fragments containing (a) the
N-terminus 342FFGV or (b) 374ARGS, by Western blot analysis on 4–12% gels loaded on an equal volume basis. Next, aggrecan and its
catabolites were extracted from the matrix and analysed for aggrecan fragments containing (c) the DIPES341 epitope and (d) the NITEGE373
epitope by Western blot analysis on 4–12% gels loaded on an equal GAG basis.
a b
c dADAM-TS4/TS5-GENERATED NEOEPITOPES WITHIN THE
C-TERMINUS OF AGGRECAN
Next, we evaluated release of specific neoepitopes
generated by ADAM-TS4/TS5 cleavage within the region
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with (a) control media or in media containing either (b) IL-1 (100 ng/ml), (c) TNF (100 ng/ml), (d) IL-1 plus IL-1ra (10 g/ml), or (e) TNF plus
neutralizing antibodies (10 g/ml). At the end of the culture period, media were analysed for aggrecan fragments (a) containing the
N-terminus KEEE1667 by Western blot analysis on 4–12% gels loaded on an equal volume basis. The higher molecular weight KEEE-reactive
band corresponds to the E-fragment, and the lower molecular weight fragment corresponds to the F-fragment. Western Blot for the GELE1480
epitope was performed on both the (b) matrix, on an equal GAG basis, and the (c) media, on an equal volume basis. Finally, (d) fragments
containing the N-terminus 1872LGQR were detected in the culture media.
a b
c dbetween the G2 and G3 domain, following IL-1 and
TNF stimulation. The most preferred cleavage site of
ADAM-TS4 and ADAM-TS5 is between Glu1667 and
Gly1668 (15 and Tortorella et al., in preparation). To evaluate
cleavage at this site, the culture media were analysed for
KEEE1667 containing aggrecan products by Western analy-
sis. We detected a 375 kDa fragment that appeared as a
doublet in the IL-1 and TNF-stimulated cultures [Fig. 4(a)].
The higher molecular weight band most probably repre-
sents a KEEE fragment with an intact G1 domain (E-
fragment), while the lower band corresponds to a fragment
with the 374ARGS amino terminus (F-fragment). However,
we cannot clearly detect the F-fragment in the ARGS-
Western [Fig. 3(B)] due to numerous ARGS-containing
fragments detected with the BC3 antibody, presumably
through further proteolytic cleavage of the fragments once
they elute into the culture media. IL-1ra and anti-TNF-
antibodies blocked the release of these fragments.
We next evaluated production of aggrecan fragments
resulting from cleavage at two other ADAM-TS4/TS5
C-terminal cleavage sites, one between residues Glu1480
and Gly1481 and the other between Glu1871 and Leu1872.
Using the anti-GELE polyclonal antibody the culture media
and cartilage extracts were analysed for GELE1481-
containing products. We detected a high MW fragment
near 350 kDa in the cartilage extract [Fig. 4(b)] and a250 kDa fragment in the culture media following IL-1 and
TNF stimulation [Fig. 4(c)]. The 350 kDa band most prob-
ably represents a fragment with an intact G1 domain
(G-fragment), consistent with it being retained in the matrix
bound to hyaluronan, and the 250 kDa band is a fragment
with the 374ARGS amino terminus (H-fragment). The
formation of these fragments was also blocked by IL-1ra
and by the TNF neutralizing antibody. Interestingly, unlike
the ARGS-Western Blot [Fig. 3(b)], the GELE blots reveal
just two specific fragments, G and H, and no smaller
molecular weight fragments containing the GELE epitope
are detected. These data suggest that the G and H frag-
ments are further processed at a fast rate at a site near the
GELE epitope before further processing towards the G2
domain. The hypothesis that further proteolytic processing
of the fragments occurs in the culture media and not the
matrix is supported by the finding that we can only detect
one ARGS-containing fragment in the cartilage matrix,
namely the 250 kDa H-fragment [see experiments below,
Fig. 5(c)].
Finally, the culture media were monitored for 1872LGQR-
containing products by Western analysis. The blot
showed that IL-1 and TNF increased the levels of a 98 kDa
LGQR-reactive fragment (I-fragment) and that this
induction was blocked by IL-1ra and by the TNF antibody
[Fig. 4(d)].
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ments were generated during IL-1 stimulated degradation.
We have found using soluble aggrecan and recombinant
ADAM-TS415 and ADAM-TS5 [Tortorella et al., in prep-
aration], that cleavage occurs preferentially at the Glu1667–
Gly1668 site, then between Glu1480 and Gly1481 with the
slowest rate at the Glu373–Ala374 site. In order to determine
whether the same order of cleavage was observed when
cartilage explants were incubated with IL-1, we evaluated
fragments within the cartilage matrix at early time points of
incubation with IL-1. We looked in the matrix as opposed to
the culture media, because it is only after 16 h that aggre-
can fragments were detected in the culture media. In the
matrix, a 375 kDa KEEE1667 fragment was detected as
early as 2 h after addition of IL-1 [Fig. 5(a)]. Next, the
GELE1480 epitope was detected at 4 h (Fig. 5(b)], and the
250 kDa 374ARGSV fragment was first detected after 8 h
[Fig. 5(c)]. Note the GELE-reactive fragment observed at
4 h was a 350 kDa band corresponding to an aggrecan
fragment with an intact G1 domain, generated by cleavage
at the Glu1480–Gly1481 bond. It was followed at 8 h by the
appearance of a 250 kDa GELE fragment with a 374ARGSV
amino terminus, corresponding to the band seen in the
BC-3 Western in Fig. 5(c), generated by cleavage of the
350 kDa fragment at the Glu373–Ala374 bond. In conclu-
sion, the fragmentation of aggrecan after stimulation of
cartilage with IL-1 follows a similar temporal sequence to
that seen when soluble aggrecan is digested with recom-
binant ADAM-TS4 and ADAM-TS5.INHIBITION OF CLEAVAGE BY A GENERAL METALLOPROTEINASE
INHIBITOR, BUT NOT AN MMP-SPECIFIC INHIBITOR
In order to confirm that IL-1-induced breakdown of
aggrecan in explant cultures of bovine articular cartilage
was mediated by ADAM-TS4 and ADAM-TS5, inhibition
studies were performed using two hydroxamic acids
which differ in their ability to inhibit the ADAM-TS enzymes.
These small molecules block metalloproteinases bychelating the zinc atom in the catalytic domain required for
enzymatic activity. XS309 is a nanomolar inhibitor of a large
number of MMPs, but is inactive at >10M in blocking
ADAM-TS4/TS5 (designated ‘MMP-specific inhibitor’). In
contrast, SE206 is a potent inhibitor of both MMPs and
ADAM-TS4/TS5 (designated ‘general metalloproteinase
inhibitor’). Explants were cultured for 72 h with IL-1
(100 ng/ml), in the presence of either XS309 (10 M)
or SE206 (10 M). Culture media were analysed for
GAG-levels and culture media as well as cartilage matrix
extracts were analysed for KEEE1667 and GELE1480
neoepitopes. It was found that the general metallo-
proteinase inhibitor, SE206, blocked IL-1-induced GAG
release into the media (Table III), and the generation of the
KEEE1667 and GELE1480 neoepitopes in the media and
cartilage extracts [Fig. 6(a)–(d)]. In contrast, XS309
showed no inhibition of either GAG release or the formation
of these neoepitopes. It is important to note that constitutive
levels of both KEEE1667- and GELE1480-containing frag-
ments were detected in the culture media of untreated
explant cultures and the release of these fragments was
also blocked by the general metalloproteinase inhibitor,
SE206. This may suggest that either ADAM-TS4 and/or
ADAM-TS5 are involved in the constitutive turnover of
aggrecan, as well as the inducible breakdown. Interest-
ingly, in the IL-1-stimulated calf articular cartilage the cul-
ture media contained two major KEEE-reactive fragments,
the 300 kDa F-fragment and the 55 kDa J-fragment
which is formed when the F-fragment is cleaved at the
Glu1480–Gly1481 bond. The latter was not detected in the
cultured media from IL-1 or TNF-stimulated cartilage from
the older cow [Fig. 4(b)].Fig. 5. IL-1-induced degradation of aggrecan in bovine articular
cartilage explants. Bovine cartilage explants were incubated for
2 h, 4 h, 6 h, 8 h, or 16 h with media containing IL-1 (100 ng/ml). At
the end of the culture period, aggrecan and aggrecan catabolites
were extracted from the cartilage matrix and analysed for (a) the
C-terminus KEEE1667, (b) the C-terminus GELE1480, or (c) the
N-terminus 374ARGS by Western blot analysis on 4–12% gels
loaded on an equal GAG basis.Table III
Cytokine-induced degradation of aggrecan in bovine articular
cartilage explants*
Treatment GAG Levels
(g/mg)
Control 1.5±0.25
IL-1 [100 ng/ml] 14.4±3.40
IL-1+SE206 [10 M] 2.2±0.32
IL-1+XS309 [10 M] 15.2±4.40
*Bovine cartilage explants were incubated for 72 h with IL-1
and MMP-inhibitors, at the specified concentrations. At the end of
the culture period, media were analysed for GAG content by
DMMB assay. Mean values±S.D. of N=6 are shown.INDUCTION OF ADAM-TS4 AND ADAM-TS5
As the experiments described above suggest a role for
ADAM-TS4 and/or ADAM-TS5 in IL-1 and TNF-induced
aggrecan cleavage, we examined whether these cyto-
kines triggered expression of ADAM-TS4 and ADAM-TS5
in bovine cartilage. We first analysed mRNA levels of
ADAM-TS4 and ADAM-TS5 by RT-PCR. Since we could
not extract sufficient amounts of RNA from the explants to
load equal amounts of RNA for the RT-PCR, the GAPDH
mRNA levels were determined for comparison [Fig. 7(a)].
ADAM-TS4 message was not detected in control explants
but it was strongly induced following IL-1 and TNF stimula-
tion and this induction was abrogated by IL-1ra or anti-TNF,
respectively [Fig. 7(b)]. In contrast, ADAM-TS5 mRNA
was present in control explants, and the levels were not
Osteoarthritis and Cartilage Vol. 9, No. 6 547dramatically altered in the presence of the pro-
inflammatory cytokines [Fig. 7(c)]. In order to avoid the
variability due to the difficulty of RNA extraction from
cartilage matrix, we repeated the experiment using bovine
articular chondrocytes cultured in confluent monolayers,
and again found that ADAM-TS5 message was expressed
constitutively while ADAM-TS4 message was induced by
IL-1 and by TNF (data not shown).
We next examined ADAM-TS4 and ADAM-TS5 protein
levels produced by cartilage explants. Western Blot analy-
sis of the culture medium of explants showed no ADAM-
TS4 or ADAM-TS5 (not shown). Only guanidinium chloride
extracts from cartilage stimulated with IL-1 or TNF were
positive for ADAM-TS4 (Fig. 8). The blot revealed three
bands with the approximate molecular weights of 60-, 45-
and 30-kDa. ADAM-TS5 was not detected under the con-
ditions employed (not shown), which may be consistent
with it being constitutively expressed but only present at
very low levels, below the detection limit of the Western
Blot analysis.Fig. 6. Blockage of IL-1-induced degradation of aggrecan in bovine articular cartilage explants. Bovine cartilage explants were incubated for
72 h with media containing IL-1 (100 ng/ml), with or without the MMP-specific inhibitor XS309 or the general metalloproteinase-inhibitor
SE206. At the end of the culture period, culture media were analysed for (a) the C-terminus KEEE1667 and (b) the C-terminus GELE1480 by
Western blot analysis on 4–12% gels loaded on an equal volume basis and the cartilage extracts were analysed for (c) KEEE1667 and (d)
GELE1480 by Western blot analysis on 4–12% gels loaded on an equal GAG basis.
a b
c dbovine articular cartilage were immuno-adsorbed with an
ADAM-TS4 or ADAM-TS5 affinity-purified polyclonal anti-
body coupled to protein-G Sepharose [Fig. 9(a)]. An
ADAM-TS1 antibody coupled to protein G Sepharose was
used as a negative control. Immunodepleted media were
tested for aggrecanase activity by incubation with purified
aggrecan for 4 h at 37°C. Following the incubation, cleav-
age of aggrecan at the Glu373–Ala374 site was monitored by
ELISA using the BC-3 monoclonal antibody. Media from
untreated, control cartilage showed no detectable levels of
activity, whereas aggrecanase activity was detected in
media from IL-1-stimulated cartilage. Immunoprecipitation
with the ADAM-TS4 antibody led to a ∼75% loss of aggre-
canase activity in media from IL-1-stimulated cartilage.
Immunoprecipitation with the ADAM-TS5 antibody led to a
∼15% decrease in activity [Fig. 9(a)]. Finally, immuno-
precipitation with the ADAM-TS1 antibody showed no
decrease in aggrecanase activity. The efficiency of
immunoprecipitation has been determined for each anti-
body. Both the ADAM-TS4 and ADAM-TS5 antisera suc-
cessfully removed 100 ng of enzyme that was added to
1 ml of DMEM medium [Fig. 9(b)]. In order to determine the
efficiency of the ADAM-TS1 immunoprecipitation, we
looked at removal of enzyme by Western Blot analysis
(data not shown). We achieved removal of >95% of all
enzymes after immunoprecipitation.IMMUNODEPLETION OF ADAM-TS4 AND ADAM-TS5
In order to confirm that ADAM-TS4 and ADAM-TS5 are
responsible for the cytokine inducible aggrecan break-
down, culture media from both control and IL-1-stimulated
548 M. D. Tortorella et al.: ADAM-TS4/TS5 in cartilage aggrecan breakdownFig. 7. Effect of IL-1 and TNF on the expression of ADAM-TS4 and
ADAM-TS5 mRNA. Cartilage explants were cultured for 72 hours
in (a) control media, (b) IL-1 (100 ng/ml), (c) TNF (100 ng/ml),
(d) IL-1 (100 ng/ml) plus IL-1ra (10 g/ml), and (e) TNF (100 ng/ml)
plus anti-TNF (10 g/ml). At the end of the culture period, RNA was
extracted from the explants, measured and used for RT-PCR for
(a) bovine GAPDH, (b) ADAM-TS4, yielding the predicted PCR
product of 693 bp, (c) ADAM-TS5, yielding the predicted PCR
product of 672 bp. Full length cDNA for ADAM-TS4 and ADAM-
TS5 was included as a positive control.
a
b
cFig. 8. Effect of IL-1 and TNF on the expression of ADAM-TS4.
Bovine cartilage explants were incubated for 72 h with (a) control
media or in media containing either (b) IL-1 (100 ng/ml), (c) TNF
(100 ng/ml), (d) IL-1 plus IL-1ra (10 g/ml), or (e) TNF plus
neutralizing antibodies (10 g/ml). At the end of the culture period,
proteins were extracted from the matrix and analysed for the
presence ADAM-TS4 on 4–12% Tris-glycine gels loaded on an
equal protein basis.Discussion
It had previously been shown that aggrecan degradation
in bovine articular cartilage in response to IL-1 and TNF is
associated with the release of products generated by
cleavage at the Glu373–Ala374 bond27. In the present
studies, we demonstrate that aggrecan fragments resulting
from cleavage at the ADAM-TS4/TS5 sensitive sites within
the C-terminus of aggrecan are also generated in cartilage
explant cultures following IL-1 and TNF stimulation. Since
we demonstrate that MMP-8 or MT1-MMP, two enzymes
that have been reported to cleave at the Glu373-Ala374
bond18,19, do not cleave at the ADAM-TS4/TS5-preferred
sites, antibodies that recognize these neoepitopes are
more specific for aggrecanase-activity. Unlike Buttner et al.,
who reported that MT1-MMP cleave rAgg1mut, a recom-
binant substrate composed of the complete interglobulardomain of aggrecan, at the Glu373–Ala374 site19, we found
that MT1-MMP cleaved native aggrecan at the MMP site
between residues Ser341 and Phe342, but not at any of
the aggrecanase sites, suggesting that the interaction of
MT1-MMP with native aggrecan is different from rAgg1mut.
We have shown that the temporal appearance of
neoepitopes generated by cleavage at these sites in
IL-1-treated cartilage corresponds with that seen upon
cleavage of aggrecan by recombinant ADAM-TS4 and
ADAM-TS5 (15 and Tortorella et al., in preparation). The
preferred site of cleavage of aggrecan by both ADAM-TS4
and ADAM-TS5 is between residues Glu1667–Gly1668,
resulting in the generation of a 375 kDa fragment with an
intact N-terminus and a new C-terminus KEEE1667. Corre-
spondingly, the 375 kDa KEEE fragment was detected first
in the matrix following IL-1 stimulation. Cleavage of aggre-
can by ADAM-TS4/TS5 between residues Glu1480 and
Gly1481 is the next most favorable, resulting in the formation
of a 350 kDa fragment with an intact N-terminus and a new
C-terminus GELE1480. This is followed by cleavage within
the IGD of aggrecan between residues Glu373 and Ala374,
resulting in the formation of a 250 kDa fragment with a
new N-terminus 374ARGS and the C-terminus GELE1480.
The GELE-reactive fragment was the second fragment
detected in the cartilage matrix following IL-1 treatment.
This fragment was first detected at 4 h, 2 h after the
KEEE-reactive fragment was detected. The ARGS-reactive
fragment was the last fragment to be detected in the matrix
following IL-1 stimulation (at about 8 h), consistent with the
kinetics of aggrecan cleavage by recombinant human
ADAM-TS4/TS5. These data provide further evidence to
support ADAM-TS4 and/or ADAM-TS5 as the enzymes
responsible for cleavage in response to IL-1 and TNF.
The conclusion that ADAM-TS4 and/or ADAM-TS5 are
degrading aggrecan in this system is corroborated by the
finding that the general metalloproteinase inhibitor, SE206,
blocked IL-1- and TNF-induced aggrecan breakdown, as
assessed by DMMB assay. This correlated with inhibition of
Osteoarthritis and Cartilage Vol. 9, No. 6 549Fig. 9. Immunodepletion of aggrecanase activity from culture media with ADAM-TS1, ADAM-TS4 or ADAM-TS5 antibodies. Two hundred l
of culture media from bovine articular cartilage stimulated with IL-1 were immunodepleted with purified rabbit IgG, ADAM-TS1, ADAM-TS4
or ADAM-TS5 antibody-coupled Sepharose. Following depletion the media incubated with 500 nM of purified aggrecan for 4 h at 37°C and
aggrecan products were analysed for the cleavage at the Glu373–Ala374site using the BC-3 monoclonal antibody in an ELISA.
Non-immunodepleted culture media was also analysed to determine the maximum aggrecanase-activity present (a). To determine the
efficiency of the immunoprecipitation using the ADAM-TS4 and ADAM-TS5 antibodies, 100 ng of the recombinant human enzyme was added
to 1 ml of DMEM media. Following the addition of either ADAM-TS4 or ADAM-TS5 the enzymes were removed by immunoprecipitation as
described above and the depleted medium was analysed for aggrecanase activity in the BC-3 ELISA (b).
a
b
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in the culture media. The MMP-specific inhibitor, XS309,
failed to inhibit aggrecan degradation, suggesting that
MMPs, such as MMP-8 and MT1-MMP which have been
shown to have the potential to cleave at the Glu373–Ala374
aggrecanase site, are unlikely to play a major role in the
breakdown of cartilage aggrecan.
An important role for ADAM-TS4 and ADAM-TS5 in
aggrecan cleavage is further supported by studies in which
immunodepletion with an ADAM-TS4 antibody led to a 75%
reduction and immunodepletion with an ADAM-TS5 anti-
body led to a 15% reduction of aggrecanase activity in the
culture media of IL-1 stimulated bovine articular cartilage.
Although a portion of the ADAM-TS4 and ADAM-TS5
protein may be retained in the cartilage matrix bound to
aggrecan and other matrix proteins, we were unable to
monitor the cartilage extracts for aggrecanase activity due
to very high levels of aggrecan not found in the culture
media and pre-existing ARGS, KEEE, GELE-reactive frag-
ments that could not be removed by anion-exchange
chromatography. Therefore, since we could not take into
account any potential matrix-associated aggrecanase
activity, our data do not clearly define which is the more
important enzyme in this system. However, from these
studies we can conclude that ADAM-TS-4 and ADAM-TS5
are responsible for approximately 90% of the aggrecanase
activity found in culture media following IL-1 stimulation of
bovine articular cartilage, and ADAM-TS4 is responsible for
the majority of this activity.
Both ADAM-TS4 and ADAM-TS5 were detected at the
message level in chondrocytes and cartilage after IL-1 and
TNF stimulation. Interestingly, ADAM-TS5 message was
detected in control cartilage, whereas ADAM-TS4 message
was not. This suggests that ADAM-TS5 is constitutively
expressed in cartilage, as has been proposed by others28,
whereas ADAM-TS4 is induced. However, since we did not
extract mRNA from cartilage immediately after dissection,
we cannot rule out the possibility that ADAM-TS4 may be
switched off or ADAM-TS5 message is switched on during
preculture in the presence of FCS.
ADAM-TS4 protein was detected in IL-1- or TNF-treated
explants, but not in the control explants. However, this
protein was not detected in the culture medium. Binding of
ADAM-TS4 to the cell surface or to matrix components may
explain this lack of detectable protein in the media. The
ADAM-TS proteins contain a thrombospondin type I motif
through which they have been shown to bind to the GAG
side chains of aggrecan29 and may bind to other matrix
components as well, or to the cell membrane as proposed
previously30, either through this motif or via the disintegrin-
like domain of the molecule. ADAM-TS5 protein was not
detected in either the matrix or in the media. This may
reflect low constitutive expression in cartilage that is not
enhanced by cytokine stimulation. Because ADAM-TS4 is
regulated by IL-1 and TNF, it is interesting to speculate that
this enzyme may be primarily responsible for the cytokine-
induced aggrecan degradation that is observed in these
studies. However, further work is needed before any
definitive conclusions can be made.
In summary, our studies suggest that ADAM-TS4 and/or
ADAM-TS5 represent the endogenous aggrecanases
responsible for a large part of the aggrecan breakdown in
bovine cartilage explants treated with IL-1 or TNF. This
could mean that they are also the enzymes responsible for
aggrecan breakdown in human disease. However, this
does not rule out the involvement of other proteinases yet
to be discovered that have similar substrate specificity toADAM-TS4 and ADAM-TS5. Recently, Flannery et al. have
detected mRNA for ADAM-TS1 ADAM-TS2, ADAM-TS3,
ADAM-TS4, ADAM-TS5, and ADAM-TS6 in bovine carti-
lage explants, bringing up the possibility that one of these
other ADAM-TS proteins may have aggrecanase activity31.
It has been reported by Kuno et al. that ADAM-TS1 can
cleave cartilage aggrecan at the Glu1871–Leu1872 bond at a
high concentration32. In our laboratory, we have shown that
ADAM-TS1 can only cleave aggrecan at the Glu1871–
Leu1872 bond at a 100-fold greater concentration than
ADAM-TS4 or ADAM-TS5. At these high concentrations,
ADAM-TS1 was still not able to cleave aggrecan at the
other cleavage sites, between Glu373 and Ala374, Glu1480
and Gly1481, Glu1667 and Gly1668, and Glu1771 and Ala1772.
For example, we found that as little as 500 pM of ADAM-
TS4 or ADAM-TS5 is needed to cleave aggrecan at all
these sites. In contrast, a concentration of 200 nM of
ADAM-TS1 was required to generate cleavage at the
Glu1871–Leu1872 bond (Tortorella et al., in preparation).
Based on the low specific activity of ADAM-TS1 for
aggrecan, we feel that ADAM-TS1 is not a cartilage
aggrecanase.
Aggrecan fragments with the amino terminal sequence
374ARGS have been identified in synovial fluid of patients
with osteoarthritis33 and inflammatory joint disease34.
Because MMP-8 and MT1-MMP are able to cleave at the
Glu373–Ala374 bond to generate 374ARGS-containing frag-
ments18,19, this neoepitope may not be specific for
aggrecanase-activity. Therefore, analysis of synovial fluid
for the presence of neoepitopes generated by the
additional cleavage sites in the chondroitin sulfate-rich
region of aggrecan will enable us to further establish the
role of these enzymes in human arthritis. Importantly, these
neoepitope antibodies will also provide us with a means of
monitoring activity of ADAM-TS4 and ADAM-TS5 at early
stages of disease, and thus may represent potential
markers of disease activity.
Although our data suggest a potential role for ADAM-TS4
and/or ADAM-TS5 in arthritic disease, bovine cartilage
explants in these studies were stimulated with 100 ng/ml
IL-1 or TNF. These levels may not be physiologically
relevant and may represent a very aggressive induction of
cartilage breakdown, probably more aggressive than that
occurring in chronic human arthritic disease. We do not
know what the in vivo triggers are for aggrecanase induc-
tion, and studies suggest that IL-1 only induces minimal
aggrecan breakdown in human articular cartilage explant
cultures (35 and Tortorella et al. unpublished data). There-
fore, our future studies will focus on determining the role of
ADAM-TS4/ADAM-TS5 in human articular cartilage aggre-
can degradation and on what factors trigger the production
of these proteins.Acknowledgments
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